Profusa delays 2025 Form 10-K after business combination
Profusa, Inc. filed a Form 12b-25 notification stating it cannot timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and expects to file no later than the fifteenth calendar day following the prescribed due date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Profusa, Inc. filed a Form 12b-25 notification stating it cannot timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and expects to file no later than the fifteenth calendar day following the prescribed due date.
The company discloses preliminary results showing a net loss of $(31.9) million for 2025 versus $(9.2) million in 2024, attributing the increase principally to $21.9 million higher general and administrative expenses related to the business combination that closed on July 11, 2025, higher R&D costs, and other transaction and financing items. Management notes a 1-for-75 reverse stock split effected February 9, 2026 and says final results will appear in the delayed Form 10-K.
Insights
Delay tied to post‑merger accounting and transaction adjustments; losses rose materially in 2025.
The filing states the company expects to file its Form 10-K within the 15‑day cure period under Rule 12b-25. The explanatory narrative links the timing to additional work needed after the Business Combination that closed on July 11, 2025, which commonly requires complex accounting, valuation, and disclosure reconciliation.
Reported preliminary figures show a net loss of $(31.9) million for 2025 versus $(9.2) million in 2024, driven by a $21.9 million increase in general and administrative expenses and higher R&D spend. Subsequent filings should confirm finalized numbers and note any auditor commentary; timing is the key dependency.
Key Figures
Key Terms
Form 12b-25 regulatory
Business Combination financial
reverse stock split market
Lumee Oxygen technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did NVACW file a Form 12b-25 delaying its 2025 Form 10-K?
What preliminary results did NVACW disclose for fiscal 2025?
Will the delayed Form 10-K include final audited results for 2025?
AI-generated analysis. How Rhea-AI works. Not financial advice.